HRP20231735T1 - Liječenje simptoma izazvanih menstrualnim ciklusom - Google Patents
Liječenje simptoma izazvanih menstrualnim ciklusom Download PDFInfo
- Publication number
- HRP20231735T1 HRP20231735T1 HRP20231735TT HRP20231735T HRP20231735T1 HR P20231735 T1 HRP20231735 T1 HR P20231735T1 HR P20231735T T HRP20231735T T HR P20231735TT HR P20231735 T HRP20231735 T HR P20231735T HR P20231735 T1 HRP20231735 T1 HR P20231735T1
- Authority
- HR
- Croatia
- Prior art keywords
- mmc
- kit
- unit dose
- use according
- menstrual cycle
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title claims 5
- 230000027758 ovulation cycle Effects 0.000 title claims 4
- QDNXSIYWHYGMCD-UHFFFAOYSA-N 2-(methylamino)-1-(3-methylphenyl)propan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC(C)=C1 QDNXSIYWHYGMCD-UHFFFAOYSA-N 0.000 claims 21
- 206010027304 Menopausal symptoms Diseases 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Claims (15)
1. Komplet koji sadrži najmanje jednu jediničnu dozu koja sadrži terapeutski učinkovitu količinu 3-metilmetkatinona (3-MMC) za upotrebu u liječenju najmanje jednog simptoma izazvanog menstruacijom kod subjekta i upute za primjenu navedenog 3-MMC-a prije, tijekom ili nakon vremena u kojem se očekuje da će se navedeni simptom izazvan menstrualnim ciklusom dogoditi, ili se dogodio, i ambalažni materijal.
2. Komplet za upotrebu prema patentnom zahtjevu 1, koji nadalje sadrži uređaj za određivanje vremena u kojem se očekuje da će se navedeni najmanje jedan simptom izazvan menstrualnim ciklusom dogoditi, ili se dogodio, u navedenom subjektu.
3. Komplet za upotrebu prema patentnom zahtjevu 1 ili 2, praćen digitalnim računalnim sučeljem za snimanje kronologije i karaktera navedenog najmanje jednog simptoma izazvanog menstrualnim ciklusom.
4. Komplet prema patentnom zahtjevu 3, pri čemu je navedeno sučelje aplikacija za mobilni telefon, komplet dalje sadrži crtični kod za preuzimanje ili aktiviranje navedene aplikacije.
5. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, pri čemu navedena jedinična doza sadrži između 5 i 100 mg 3-MMC.
6. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, pri čemu navedena jedinična doza sadrži između 10 i 60 mg 3-MMC.
7. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, pri čemu navedena jedinična doza sadrži 12,5 mg 3-MMC.
8. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, pri čemu navedena jedinična doza sadrži 25 mg 3-MMC.
9. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, pri čemu navedena jedinična doza sadrži 50 mg 3-MMC.
10. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, koji sadrži najmanje jednu jediničnu dozu od 12,5 mg 3-MMC i najmanje jednu jediničnu dozu od 25 mg 3-MMC.
11. Komplet za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, koji sadrži najmanje jednu jediničnu dozu od 25 mg 3-MMC i najmanje jednu jediničnu dozu od 50 mg 3-MMC.
12. Komplet za upotrebu u liječenju najmanje jednog simptoma izazvanog premenopauzom, perimenopauzom i menopauzom kod subjekta kojem je to potrebno, a koji sadrži najmanje jednu jediničnu dozu koja sadrži terapeutski učinkovitu količinu 3-metilmetkatinona (3-MMC).
13. Komplet za upotrebu prema patentnom zahtjevu 12, pri čemu navedena jedinična doza sadrži između 5 i 100 mg 3-MMC, 10 i 60 mg 3-MMC ili 12,5 mg 3-MMC.
14. Komplet za upotrebu prema patentnom zahtjevu 12, koji sadrži najmanje jednu jediničnu dozu od 12,5 mg 3-MMC i najmanje jednu jediničnu dozu od 25 mg 3-MMC.
15. Komplet za upotrebu prema patentnom zahtjevu 12, koji sadrži najmanje jednu jediničnu dozu od 25 mg 3-MMC i najmanje jednu jediničnu dozu od 50 mg 3-MMC.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891438P | 2019-08-26 | 2019-08-26 | |
| PCT/IB2020/057967 WO2021038460A1 (en) | 2019-08-26 | 2020-08-26 | Treatment of menstrual cycle-induced symptoms |
| EP20772102.8A EP4021433B1 (en) | 2019-08-26 | 2020-08-26 | Treatment of menstrual cycle-induced symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231735T1 true HRP20231735T1 (hr) | 2024-03-15 |
Family
ID=72517274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231735TT HRP20231735T1 (hr) | 2019-08-26 | 2020-08-26 | Liječenje simptoma izazvanih menstrualnim ciklusom |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11559502B2 (hr) |
| EP (1) | EP4021433B1 (hr) |
| JP (1) | JP2022545960A (hr) |
| KR (1) | KR20220069014A (hr) |
| CN (1) | CN114555070A (hr) |
| AU (1) | AU2020335372A1 (hr) |
| BR (1) | BR112022003686A2 (hr) |
| CA (1) | CA3152069A1 (hr) |
| ES (1) | ES2967484T3 (hr) |
| HR (1) | HRP20231735T1 (hr) |
| HU (1) | HUE064596T2 (hr) |
| IL (1) | IL290880A (hr) |
| MA (1) | MA56998B1 (hr) |
| MX (1) | MX2022002400A (hr) |
| PL (1) | PL4021433T3 (hr) |
| WO (1) | WO2021038460A1 (hr) |
| ZA (1) | ZA202203367B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11559502B2 (en) | 2019-08-26 | 2023-01-24 | Period Pill Bv | Treatment of menstrual cycle-induced symptoms |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389670A (en) * | 1993-12-21 | 1995-02-14 | Eli Lilly Company | Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder |
| WO2004004638A2 (en) | 2002-07-02 | 2004-01-15 | Galileo Pharmaceuticals, Inc. | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| US20040127409A1 (en) | 2002-11-07 | 2004-07-01 | Milkhaus Laboratory, Inc. | Method of treatment of psychological conditions by administration of nerve growth factor |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| WO2006012563A2 (en) | 2004-07-23 | 2006-02-02 | The Regents Of The University Of California | Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle |
| US20080262071A1 (en) | 2004-09-17 | 2008-10-23 | Timothy Dinan | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder |
| US20080207601A1 (en) * | 2005-04-07 | 2008-08-28 | Hythiam , Inc. | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence |
| CN101175740A (zh) | 2005-04-22 | 2008-05-07 | 惠氏公司 | 二氢苯并呋喃衍生物和其用途 |
| WO2006116158A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Benzodioxane and benzodioxolane derivatives and uses thereof |
| US20070098819A1 (en) | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
| US20070255278A1 (en) | 2006-04-28 | 2007-11-01 | Nobis Rudolph H | Apparatus and method for deploying a cutting element during an endoscopic mucosal resection |
| US20080160083A1 (en) | 2007-01-03 | 2008-07-03 | Jarret Morrow | Composition and method for treatment of premenstrual symptoms |
| WO2010015029A1 (en) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
| US20100172916A1 (en) | 2008-11-10 | 2010-07-08 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US9119865B2 (en) | 2009-10-27 | 2015-09-01 | Lipogen Ltd. | Compositions and methods for alleviating symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder |
| WO2013171146A1 (en) * | 2012-05-15 | 2013-11-21 | Lts Lohmann Therapie-Systeme Ag | Oral film containing enteric release opiate resinate |
| BR102013013564A2 (pt) | 2013-05-31 | 2015-07-07 | Ems Sa | Composição para tratamento ou redução de sintomas relacionados à tensão pré-menstrual (tpm), transtorno disfórico pré-menstrual (tdpm), pré-menopausa, menopausa ou desordens hormonais femininas, forma farmacêutica contendo dita composição, processo para produzir dita forma farmacêutica e uso de dita composição |
| KR102262306B1 (ko) | 2013-07-04 | 2021-06-09 | (주)아모레퍼시픽 | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 |
| US10575829B2 (en) | 2014-09-03 | 2020-03-03 | Earlysense Ltd. | Menstrual state monitoring |
| TWI774660B (zh) | 2016-03-08 | 2022-08-21 | 日商大塚製藥股份有限公司 | 女性特有之身體及/或精神不快症狀之改善劑 |
| WO2018125019A2 (en) * | 2016-12-30 | 2018-07-05 | Istanbul Üni̇versi̇tesi̇ | Use of some mirnas for the diagnosis and treatment of diseases associated with insulin |
| US20200360311A1 (en) | 2017-08-03 | 2020-11-19 | Mind Medicine, Inc. | Use of 3-methylmethcathinone |
| US11559502B2 (en) | 2019-08-26 | 2023-01-24 | Period Pill Bv | Treatment of menstrual cycle-induced symptoms |
-
2020
- 2020-08-26 US US17/637,859 patent/US11559502B2/en active Active
- 2020-08-26 EP EP20772102.8A patent/EP4021433B1/en active Active
- 2020-08-26 HR HRP20231735TT patent/HRP20231735T1/hr unknown
- 2020-08-26 KR KR1020227009988A patent/KR20220069014A/ko unknown
- 2020-08-26 JP JP2022513642A patent/JP2022545960A/ja active Pending
- 2020-08-26 MX MX2022002400A patent/MX2022002400A/es unknown
- 2020-08-26 WO PCT/IB2020/057967 patent/WO2021038460A1/en active Application Filing
- 2020-08-26 PL PL20772102.8T patent/PL4021433T3/pl unknown
- 2020-08-26 MA MA56998A patent/MA56998B1/fr unknown
- 2020-08-26 CN CN202080072247.8A patent/CN114555070A/zh active Pending
- 2020-08-26 HU HUE20772102A patent/HUE064596T2/hu unknown
- 2020-08-26 BR BR112022003686A patent/BR112022003686A2/pt unknown
- 2020-08-26 AU AU2020335372A patent/AU2020335372A1/en active Pending
- 2020-08-26 CA CA3152069A patent/CA3152069A1/en active Pending
- 2020-08-26 ES ES20772102T patent/ES2967484T3/es active Active
-
2022
- 2022-02-24 IL IL290880A patent/IL290880A/en unknown
- 2022-03-22 ZA ZA2022/03367A patent/ZA202203367B/en unknown
-
2023
- 2023-01-06 US US18/093,846 patent/US20230145635A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202203367B (en) | 2023-10-25 |
| ES2967484T3 (es) | 2024-04-30 |
| MA56998B1 (fr) | 2023-12-29 |
| PL4021433T3 (pl) | 2024-03-11 |
| WO2021038460A1 (en) | 2021-03-04 |
| CN114555070A (zh) | 2022-05-27 |
| CA3152069A1 (en) | 2021-03-04 |
| US11559502B2 (en) | 2023-01-24 |
| US20220265581A1 (en) | 2022-08-25 |
| EP4021433B1 (en) | 2023-10-04 |
| JP2022545960A (ja) | 2022-11-01 |
| US20230145635A1 (en) | 2023-05-11 |
| MX2022002400A (es) | 2022-06-08 |
| AU2020335372A1 (en) | 2022-04-07 |
| IL290880A (en) | 2022-04-01 |
| KR20220069014A (ko) | 2022-05-26 |
| EP4021433C0 (en) | 2023-10-04 |
| BR112022003686A2 (pt) | 2022-05-24 |
| HUE064596T2 (hu) | 2024-03-28 |
| EP4021433A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171470T1 (hr) | Automatizirano raspakiravanje prijenosnih izvršnih datoteka | |
| HRP20231735T1 (hr) | Liječenje simptoma izazvanih menstrualnim ciklusom | |
| JP2013503165A5 (hr) | ||
| CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
| HRP20230616T1 (hr) | Disperzivni pripravci | |
| CO2021001979A2 (es) | Formas farmacéuticas orales biodisponibles | |
| HRP20211621T1 (hr) | Imatinib za uporabu u liječenju moždanog udara | |
| AR038143A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
| FI3509595T3 (fi) | Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita | |
| CL2004000767A1 (es) | Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos. | |
| AR044450A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| MX2023003401A (es) | Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo. | |
| MX2016009226A (es) | Combinaciones farmaceuticas. | |
| RU2017129085A (ru) | Новый состав N-карбамоилметил-4-фенил-2-пирролидона | |
| UY31041A1 (es) | Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales para usar en enfermedades mediadas por brca | |
| FR1133007A (fr) | Seringue à piston, notamment pour usage médical | |
| EA202092800A1 (ru) | Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом | |
| ES268807A1 (es) | Un dispositivo de disco limpiador para la limpieza del suelo de los tamices | |
| MA56448A (fr) | Compositions pharmaceutiques pour peptides co-agonistes du glucagon et du glp-1 | |
| LING et al. | Expression of ATF4 in mouse endometrium during the estrus cycle | |
| Leonova et al. | Development of composition capsules for treatment of varicose veins | |
| FR1248279A (fr) | Ampoule, notamment à usage pharmaceutique | |
| CL2022000179A1 (es) | Terapia contra la ibd mediante inhibición de drd3 en linfocitos t reguladores | |
| Dingwall et al. | Combination pill effective, but expensive | |
| BR112019002909A2 (pt) | composição melhorada de teneligliptina e metformina, e processo para preparação da mesma |